Halle (Saale), 23.11.2021. PerioTrap has received the official statement of its first Scientific Advisory Board Meeting which was held on October 19^th at the company’s offices.

The board consists of leaders and experts in the field of drug design, periodontitis fundamental and clinical research, microbiology as well as pharmaceutical technology. The shared feedback of its internal discussion endorses PerioTrap’s Research Program which was found to be “up and running in a remarkable short time frame. Both drug programs showed significant progress in the last year.”

Dr. Mirko Buchholz, CSO and Co-Founder of PerioTrap Pharmaceuticals states: “We are very happy to welcome these highly recognized experts of the periodontal and drug development fields and to share with them our latest research advancements. To receive such a positive opinion and advice makes us proud and very much confirms us to keep following our route of development.”

PerioTrap’s longterm release formulation of minocycline is about to enter clinical testing while its new chemical entity that addresses the microbiome shift in periodontitis is currently being tested in vivo. In general, it is being advised to stay focused to achieve the next critical milestones.

If you would like to learn more about our programs check out our latest publications.